Search

Adrenal cortical carcinoma is a rare and aggressive cancer with poor prognosis. Cases usually present with signs and symptoms of excessive hormone production. Hyperglycemia and Cushing syndrome are common, but tumor-associated hypoglycemia due to paraneoplastic secretion of insulin-like growth factor-2 (termed Anderson's syndrome) is uncommon. Given the rarity of adrenal cortical carcinoma, diagnosis and management of associated complications is challenging. In this study, we present a case of metastatic adrenal cortical carcinoma with a myriad of hormonal abnormalities. We will also briefly review literature regarding genetic association, pathophysiology, treatment options, and prognosis. [ABSTRACT FROM AUTHOR]

Copyright of Oncologist is the property of Oxford University Press / USA and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Lung cancer is the leading cause of cancer-related death worldwide. The majority of these cancers are non–small-cell lung cancer, of which adenocarcinoma is the most common histologic subtype. Most patients are diagnosed at advanced stages when systemic treatment is needed. Whereas prognosis has improved for patients with targetable driver mutations, the majority of patients do not possess tumors with such molecular mutations. Platinum-based chemotherapy has traditionally been the mainstay of treatment, although in recent years immunotherapy has emerged as a treatment option and can result in robust and durable treatment responses in a subset of patients. Recent clinical trials on novel immunotherapy combinations and immunochemotherapy combinations may broaden the number of patients that may benefit from checkpoint inhibitors and elicit responses in those who otherwise may not have experienced a response to monotherapy with an immunotherapy drug. This review will outline the currently available therapies for the first-line treatment of metastatic adenocarcinoma that do not possess a driver mutation and provide a recommended approach and algorithm by which to select the best first-line therapy. [ABSTRACT FROM AUTHOR]

Liquid biopsy, precision oncology, molecular target, tumor heterogeneity, drug resistance, tumor burden, cfDNA Cancer Center GI Oncology Subspecialty Clinic Pooja Ghatalia 1, Chad H. Smith 1, Arthur Winer 1, Jiangtao Gou 2, Lesli A. Kiedrowski 3, Michael Slifker 2, Patricia D. Saltzberg 1, Nicole Bubes 1, Fern M. Anari 1, Vineela Kasireddy 1, Asya Varshavsky 1, Yang Liu 1, Eric A. Ross 2 and Wafik S. El-Deiry 1 * 1 Department of Hematology/Oncology, Fox Chase Cancer Center, Philadelphia, PA, United States, 2 Department of Biostatistics and Bioinformatics, Fox Chase Cancer Center, Philadelphia, PA, United States, 3 Guardant Health, Redwood City, CA, United States Keywords: liquid biopsy, precision oncology, molecular target, tumor heterogeneity, drug resistance, tumor burden, cfDNA A Corrigendum on Clinical Utilization Pattern of Liquid Biopsies (LB) to Detect Actionable Driver Mutations, Guide Treatment Decisions and Monitor Disease Burden During Treatment of 33 Metastatic Colorectal Cancer (mCRC) Patients (pts) at a Fox Chase Cancer Center GI Oncology Subspecialty Clinic By Ghatalia P, Smith CH, Winer A, Gou J, Kiedrowski LA, Slifker M, Saltzberg PD, Bubes N, Anari FM, Kasireddy V, Varshavsky A, Liu Y, Ross EA and El-Deiry WS (2019). [Extracted from the article]